Promomed took the first place in sales of GLP‑1 class drugs

Promomed has become the new leader in sales of GLP-1 drugs in the Russian market. According to AlphaRM's retail audit, in the first eight weeks of 2026, tirzepatide took the lead among molecules with a share of 65.1% compared to 34.5% for semaglutide, while Promomed's share in the segment reached 51.9%.